Allogeneic hematopoietic cell transplantation in Farber disease

Journal of Inherited Metabolic Disease
Karoline EhlertJosef Vormoor

Abstract

Farber disease (FD) is a rare, lysosomal storage disorder caused by deficient acid ceramidase activity. FD has long been considered a fatal disorder with death in the first three decades of life resulting either from respiratory insufficiency as a consequence of airway involvement or from progressive neurodegeneration because of nervous system involvement. Peripheral symptoms associated with FD, including inflammatory joint disease, have been described to improve relatively rapidly after hematopoietic cell transplantation (HCT). To evaluate the disease-specific status and limitations in the long-term follow-up after HCT, investigate genotype/phenotype correlations and the benefit of allogeneic HCT in FD patients with nervous system involvement. Transplant- and disease-related information of ten FD patients was obtained by using a questionnaire, physicians' letters and additional telephone surveys. ASAH1 gene mutations were identified to search for genotype/phenotype correlations. After mainly busulfan-based preparative regimens, all patients engrafted with one late graft loss. The inflammatory symptoms resolved completely in all patients. Abnormal neurologic findings were present pre-transplant in 4/10 patients, post-transplant...Continue Reading

References

Jun 17, 1989·Lancet·G SouilletJ E de Vries
Nov 1, 1986·Pediatric Neurology·L EviatarA Gochoco
Mar 1, 1984·The Journal of Pediatrics·S E AntonarakisW H Zinkham
Sep 1, 2000·Bone Marrow Transplantation·A M YeagerH W Moser
Mar 18, 2003·Journal of Inherited Metabolic Disease·T MuramatsuK Inui
Jan 15, 2004·The Journal of Pediatrics·Josef VormoorJohannes Roth
Jul 9, 2010·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·L Cvitanovic-SojatT Levade
Jun 19, 2012·American Journal of Human Genetics·Jie ZhouJudith Melki
Feb 7, 2013·Journal of Inherited Metabolic Disease·Mikhail M KostikThierry Levade
May 18, 2013·EMBO Molecular Medicine·Abdulfatah M AlayoubiJeffrey A Medin
Jun 6, 2014·Nature·Michael Maceyka, Sarah Spiegel
Jul 31, 2014·British Journal of Haematology·Jaap Jan BoelensRobert F Wynn

❮ Previous
Next ❯

Citations

Jun 17, 2020·Indian Journal of Pediatrics·Aakanksha ChoudharySuvasini Sharma
May 28, 2019·Clinica Chimica Acta; International Journal of Clinical Chemistry·Patricia DubotThierry Levade

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.